AC Immune AG（ACIU）财务数据ACIUAC Immune AG

Evaluating the bottom line, AC Immune AG maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.89%, while the net margin is 12.40%. These profitability ratios, combined with a Return on Equity (ROE) of -78.53%, provide a clear picture of how effectively ACIU converts its operational activities into shareholder value.

In the context of the broader market, ACIU competes directly with industry leaders such as VNDA and LFCR. With a market capitalization of $237.63M, it holds a significant position in the sector. When comparing efficiency, ACIU's gross margin of 100.00% stands against VNDA's 89.02% and LFCR's 35.34%. Such benchmarking helps identify whether AC Immune AG is trading at a premium or discount relative to its financial performance.

AC Immune has shown a significant recovery in Q2 2026 with a net income of 2.4 million CHF, a stark contrast to the losses reported in previous quarters. The gross margin remains strong at 100%, indicating efficient cost management. The company also holds 92.9 million CHF in cash, which supports its ongoing operations and clinical trials.